<DOC>
	<DOCNO>NCT01346371</DOCNO>
	<brief_summary>The purpose study compare effect Bepreve® artificial-tear eye drop quality tear .</brief_summary>
	<brief_title>The Effect BEPREVE 1.5 % Tear Film Osmolarity Tear Film Lipid Layer</brief_title>
	<detailed_description>This single-center , randomize , parallel group , placebo-controlled study evaluate effect BEPREVE compare placebo eye drop measurement tear film osmolarity tear film lipid layer patient allergic conjunctivitis . Subjects screen study day one dosing test article . Subjects sign inform consent form meet inclusion/exclusion criterion eligible participation study . They assign sequentially , accord computer generate randomization list , ratio 1:1 receive either BEPREVE™ ( bepotastine besilate ophthalmic solution ) 1.5 % REFRESH TEARS® Lubricant Eye Drops ( 1:1 ) . Subjects instill one drop test article either BEPREVE™ REFRESH TEARS® study eye twice daily maximum 60 day . Subjects see evaluation Days 0 , 28±3 , 56±3 follow randomization .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Are male female least 18 year age diagnose allergic conjunctivitis . 2 . Have document positive skin prick puncture test least one ( 1 ) seasonal allergen ( e.g. , grass , tree , weed , allergen ) within two ( 2 ) year Visit 1 . 3 . Agree ocular drop study eye within 2 day prior initiation dose test article throughout duration study . 4 . Have Best Corrected Visual Acuity 20/200 good either eye . 5 . Are willing/able follow instruction study investigator his/her staff . 6 . Be willing/able return require study visit , follow instruction study investigator his/her staff . 7 . Are able selfadminister test article ( caregiver available instill dose test article ) . 8 . Have sign informed consent approve Institutional Review Board Independent Ethics Committee . 1 . Have know hypersensitivity either BEPREVE™ REFRESH TEARS® component test article ( include `` procedural '' medication anesthetic and/or fluorescein drop , dilate drop , etc. ) . 2 . Have active corneal pathology note study eye screen visit . Active corneal pathology define corneal pathology nonstable , great mild , compromise assessment safety efficacy treatment . 3 . Have use topical , ocular , inhaled systemic steroid within 14 day prior screen . 4 . Have history abuse alcohol/drugs within six month prior screen visit . 5 . Are pregnant nursing/lactating . 6 . Have participate study investigational drug device within 30 day prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Allergic</keyword>
	<keyword>conjunctivitis</keyword>
	<keyword>Allergic conjunctivitis</keyword>
</DOC>